NCT05439681 is a NA clinical trial of Theranova 400 in Troponin T, sponsored by Medical University of Graz.

Who is sponsoring NCT05439681?

NCT05439681 is sponsored by Medical University of Graz.

What drugs are being tested in NCT05439681?

Interventions in NCT05439681: Theranova 400, FX 10, FX CorDiax 800, HDF.

What condition does NCT05439681 study?

NCT05439681 studies Troponin T.

Is NCT05439681 still recruiting?

NCT05439681 is currently completed. Last updated 2 March 2023.

Last reviewed 2023-03-02 · How we verify

NCT05439681

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hs-Troponin T Kinetics in Patients Treated With MCO Membranes Compared to High-flux, Low-flux Membranes and HDF

Completed NA Last updated 2 March 2023

What this trial tests

NA trial testing Theranova 400 in Troponin T in 22 participants. Completed in 24 December 2022.

Timeline

12 August 2022

Primary endpoint
24 December 2022

24 December 2022

Quick facts

Lead sponsor	Medical University of Graz
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	diagnostic
Enrollment	22
Start date	12 August 2022
Primary completion	24 December 2022
Estimated completion	24 December 2022
Sites	1 location across Austria

Drugs / interventions tested

Theranova 400
FX 10
FX CorDiax 800
HDF

Conditions studied

Troponin T — all drugs for Troponin T →

Sponsor

Medical University of Graz

Who can join

18 and older, any sex, with Troponin T. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, 24 prevalent hemodialysis patients will undergo four regular hemodialysis sessions during which four different treatments will be performed. * Treatment 1: MCO membrane (=medium cut off) * Treatment 2: low flux membrane * Treatment 3: high flux membrane * Treatment 4: HDF(=hemodiafiltration) treatment with high flux membrane So far, there is no data on cardiac bioenzyme levels during hemodialysis on the MCO membrane, thus, a acute elevation during hemodialysis might be mitigated by increased clearance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Theranova 400

Trials testing the same drug.

NCT04160351 — A Randomised, Open-Label, Cross Over Group, Single-Centre Controlled Study To Evaluate The Clinical Performance Of Mediu · NA · completed

Other Medical University of Graz trials

Trials by the same sponsor.

NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05439681 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
Last refreshed: 2 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05439681.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing